Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition - Narrative (Details)

v3.21.2
Revenue Recognition - Narrative (Details)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
segment
Sep. 30, 2020
USD ($)
Revenue from Contract with Customer [Abstract]        
Number of operating segments | segment     2  
Revenue payment terms     Collection of consideration the Company expects to receive typically occurs within 30 to 90 days of billing for commercial insurance, Medicare and other governmental and self-pay payers and within 60 to 90 days of billing for client payers.  
Increase in Pharma contract assets     $ 0.2  
Pharma contract asset, increase (as a percent) 11.00%   11.00%  
Increase in Pharma contract liabilities     $ 1.5  
Increase (decrease) in Pharma contract liabilities (as a percent)     31.00%  
Increase (decrease) in capitalized commissions (as a percent)     (7.00%)  
Pharma contract liability, revenue recognized $ 0.4 $ 0.5 $ 4.2 $ 2.1
Amortization of contract commissions $ 0.2 $ 0.3 $ 0.9 $ 0.6